OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	247
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	223
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	206
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	185
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	161
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	160
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	160
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	157
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	150
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	150
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	140
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	137
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	128
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	122
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	120
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	119
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	115
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	114
Commentary on oncolytic viruses: past, present, and future	114
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	113
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	111
Is immunotherapy safe and effective in patients with VEXAS syndrome?	108
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	106
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	106
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	103

Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	103
Biomarkers for response to TIL therapy: a comprehensive review	102
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	99
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	99
Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urotheli	97
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	97
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	96
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	95
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	93
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	91
iRECIST and atypical patterns of response to immuno-oncology drugs	90
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	88
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	87
T-cell tolerant fraction as a predictor of immune-related adverse events	87
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	87
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	86
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	86
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	85
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	85
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	83
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	83
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	83
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	82
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	82
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	80
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	77
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	76
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	75
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	75
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	75
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	75
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	73
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	72
Sulforaphane activates CD8⁺ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	72
Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment	72
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8⁺ T cell-dependent antitumor immunity and abscopal effect after local irradiation	72
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	71
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	71
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	71
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	70
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	69
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	69
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	69